<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870854</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-PA #1723</org_study_id>
    <nct_id>NCT03870854</nct_id>
  </id_info>
  <brief_title>Paced Electrogram Feature Analysis (PEFA) for Ablation Targeting in Ischaemic Ventricular Tachycardia</brief_title>
  <acronym>PEFA-VT</acronym>
  <official_title>Paced Electrogram Feature Analysis (PEFA) for Ablation Targeting in Ischaemic Ventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Damian Redfearn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Canadian multicentre prospective cohort study of 40 patients with ischaemic heart disease and&#xD;
      therapy from an implantable cardioverter defibrillator (ICD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paced Electrogram Feature Analysis is employed to elucidate VT isthmus sites and target Type&#xD;
      I sites for ablation to prevent recurrent VT/VF.&#xD;
&#xD;
      The trial hypothesis is: catheter ablation employing PEFA will, in comparison to published&#xD;
      data, reduce the composite outcome of death at any time, appropriate ICD shock, ventricular&#xD;
      tachycardia storm or treated sustained ventricular tachycardia below the detection rate of&#xD;
      the ICD or incessant VT for patients with prior myocardial infarction and sustained&#xD;
      ventricular tachycardia or fibrillation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a Canadian multi-centre prospective cohort study of 40 participants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>3 years</time_frame>
    <description>a composite of death - any time post procedure myocardial infarction and sustained ventricular tachycardia or fibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Appropriate ICD shock</measure>
    <time_frame>3 years</time_frame>
    <description>Time to first appropriate ICD shock - any time post procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VT storm</measure>
    <time_frame>3 years</time_frame>
    <description>Time to 3 or more episodes of VT within 24 hours - any time post procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treated sustained VT below the detection rate of the ICD</measure>
    <time_frame>3 years</time_frame>
    <description>Time to any sustained VT below the detection rate of the ICD; e.g. by external cardioversion, pharmacologic conversion, or manual ICD therapy - any time post procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incessant VT</measure>
    <time_frame>3 years</time_frame>
    <description>Time to incessant VT defined as a sustained ventricular arrhythmia which does not terminate despite appropriate external cardioversion/defibrillation or ICD antitachycardia pacing or shocks, or terminates but reinitiates within â‰¤5 seconds - any time post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appropriate anti-tachycardia pacing (ATP) from ICD</measure>
    <time_frame>3 years</time_frame>
    <description>Appropriate anti-tachycardia pacing (ATP) from ICD - any time post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inducible for ventricular arrhythmia</measure>
    <time_frame>3 years</time_frame>
    <description>Number of inducible for ventricular arrhythmia following catheter ablation guided by PEFA protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular arrhythmia events</measure>
    <time_frame>3 years</time_frame>
    <description>This is a composite of appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion, and incessant VT - any time during or after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation and De-escalation of antiarrhythmic medication</measure>
    <time_frame>3 years</time_frame>
    <description>Any increase or decrease in the dosage of antiarrhythmic medication either due to inefficacy or side effects will be assessed - any time post procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ischemic Ventricular Tachycardia (VT)</condition>
  <arm_group>
    <arm_group_label>PEFA targeted substrate ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of PEFA strategy to identify and target VT isthmuses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PEFA VT ablation technique</intervention_name>
    <description>Catheter ablation guided by PEFA technique</description>
    <arm_group_label>PEFA targeted substrate ablation</arm_group_label>
    <other_name>Paced electrogram feature analysis or 'PEFA'</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  greater than 18 years of age&#xD;
&#xD;
          -  Ischaemic heart disease and prior myocardial infarction (using the international&#xD;
             definition of MI: Q waves or imaging evidence of regional myocardial akinesis/thinning&#xD;
             in the absence of a non-ischemic cause with documentation of prior ischaemic injury)&#xD;
&#xD;
          -  Eligible for catheter ablation as standard of care&#xD;
&#xD;
          -  Implantable Cardioverter Defibrillator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to provide consent&#xD;
&#xD;
          -  Both mechanical aortic and mitral valve&#xD;
&#xD;
          -  LV thrombus,&#xD;
&#xD;
          -  NYHA class IV heart failure symptoms&#xD;
&#xD;
          -  Contraindication to heparin&#xD;
&#xD;
          -  Survival limited to &lt;1 year in estimation of attending care team,&#xD;
&#xD;
          -  Prior VT ablation Exclusion to standard of care VT catheter ablation procedure such as&#xD;
&#xD;
          -  Active ischaemia (acute thrombus diagnosed by coronary angiography, or dynamic ST&#xD;
             segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-&#xD;
             induced arrhythmia), had recent acute coronary syndrome within 30 days thought to be&#xD;
             due to acute coronary arterial thrombosis, or have CCS functional class IV angina.&#xD;
             Note that biomarker level elevation alone after ventricular arrhythmias does not&#xD;
             denote acute coronary syndrome or active ischemia.&#xD;
&#xD;
          -  Non-ischaemic cardiomyopathy because of reduced ablation success and PEFA has not been&#xD;
             examined in the context of a non-ischaemic cardiomyopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damian Redfearn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kingston Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharlene Hammond</last_name>
    <phone>613-533-2148</phone>
    <email>Sharlene.Hammond@kingstonhsc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharlene Hammond</last_name>
      <phone>613-533-2148</phone>
      <email>Sharlene.Hammond@kingstonhsc.ca</email>
    </contact>
    <contact_backup>
      <email>KGHRI.CARU@kingstonhsc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Damian Redfearn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Porretta, HBSc</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>32268</phone_ext>
      <email>Alexander.Porretta@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Lorne Gula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institutation</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Madhuri Thommandru</last_name>
      <phone>613-696-7000</phone>
      <phone_ext>19080</phone_ext>
      <email>mthommandru@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Pablo Nery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Damian Redfearn</investigator_full_name>
    <investigator_title>MB CHB MD MRCPI FRCPC Professor of Medicine, Kingston Health Sciences Centre</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

